Pfizer receives USFDA approval for Elrexfio for the treatment of relapsed or refractory multiple myeloma
ELREXFIO’s label contains a boxed warning for cytokine release syndrome and neurologic toxicity
ELREXFIO’s label contains a boxed warning for cytokine release syndrome and neurologic toxicity
Subscribe To Our Newsletter & Stay Updated